Results 1 to 10 of about 12,213 (109)
The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist. [PDF]
PLoS ONE, 2013 Nebivolol, a third generation β-adrenoceptor (β-AR) antagonist (β-blocker), causes vasodilation by inducing nitric oxide (NO) production. The mechanism via which nebivolol induces NO production remains unknown, resulting in the genesis of much of the ...
Catherine E Erickson +8 more
doaj +17 more sources
Frontiers in Allergy, 2022 As a novel receptor that efficiently elicits degranulation upon binding to one of its numerous ligands, MRGPRX2 has moved to the center of attention in mast cell (MC) research.
Zhao Wang +12 more
doaj +1 more source
Frontiers in Pharmacology, 2022 The δ-opioid receptor (δOR) has been considered as a therapeutic target in multiple neurological and neuropsychiatric disorders particularly as δOR agonists are deemed safer alternatives relative to the more abuse-liable µ-opioid receptor drugs. Clinical
Arryn T. Blaine +12 more
doaj +1 more source
ClickArr: a novel, high-throughput assay for evaluating β-arrestin isoform recruitment
Frontiers in Pharmacology, 2023 Background: Modern methods for quantifying signaling bias at G protein–coupled receptors (GPCRs) rely on using a single β-arrestin isoform. However, it is increasingly appreciated that the two β-arrestin isoforms have unique roles, requiring the ability ...
Alexander R. French +6 more
doaj +1 more source
CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7. [PDF]
PLoS ONE, 2014 Chemokine CXCL12 promotes growth and metastasis of more than 20 different human cancers, as well as pathogenesis of other common diseases. CXCL12 binds two different receptors, CXCR4 and CXCR7, both of which recruit and signal through the cytosolic ...
Nathaniel L Coggins +7 more
doaj +1 more source
Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. [PDF]
PLoS ONE, 2014 β-arrestins, ubiquitous cellular scaffolding proteins that act as signaling mediators of numerous critical cellular pathways, are attractive therapeutic targets because they promote tumorigenesis in several tumor models.
Jonathan W Kotula +7 more
doaj +1 more source
Frontiers in Endocrinology, 2020 Establishing reliable prognostic factors as well as specific targets for new therapeutic approaches is an urgent requirement in advanced ovarian cancer. For several tumor entities, the ubiquitously spread scaffold protein β-arrestin 2, a multifunctional ...
Bastian Czogalla +17 more
doaj +1 more source
Distinct and shared roles of β-arrestin-1 and β-arrestin-2 on the regulation of C3a receptor signaling in human mast cells. [PDF]
PLoS ONE, 2011 The complement component C3a induces degranulation in human mast cells via the activation of cell surface G protein coupled receptors (GPCR; C3aR).
Arpana Vibhuti +4 more
doaj +1 more source
Frontiers in Oncology, 2023 Hormones may be key factors driving cancer development, and epidemiological findings suggest that steroid hormones play a crucial role in ovarian tumorigenesis.
Ji-Won Ryu +12 more
doaj +1 more source
Phosphorylation of C3a receptor at multiple sites mediates desensitization, β-arrestin-2 recruitment and inhibition of NF-κB activity in mast cells. [PDF]
PLoS ONE, 2012 Phosphorylation of G protein coupled receptors (GPCRs) by G protein coupled receptor kinases (GRKs) and the subsequent recruitment of β-arrestins are important for their desensitization.
Kshitij Gupta +3 more
doaj +1 more source